All In Biotech

NDA 020866 · Veroscience

Cycloset

Bromocriptine Mesylate · Oral

Last checked: Nov 20, 2026Latest source record: Aug 17, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

May 5, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

47

13 Phase 3, 3 recruiting

FAERS reports

646

513 serious, 30 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 12, 2026.

CYCLOSET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. CYCLOSET is an ergot derivative indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Should not be used to treat type 1 diabetes or diabetic ketoacidosis. ( 1 ) Limited efficacy data in combination with thiazolidinediones. ( 1 ) Efficacy has not been confirmed in combination with insulin. ( 1 ) Limitations of Use CYCLOSET should not be used to treat type 1 diabetes or diabetic ketoacidosis. Limited efficacy data in combination with thiazolidinediones. Efficacy has not been confirmed in combination with insulin.

Mechanism: CYCLOSET contains bromocriptine mesylate, a sympatholytic, dopamine D2 receptor agonist. In patients with type 2 diabetes, timed morning administration of CYCLOSET is associated with increased insulin sensitivity and glucose disposal and reduced fasting and postprandial hyperglycemia throughout the meals of the day without raising plasma insulin levels.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CYCLOSET · BROMOCRIPTINE MESYLATE EQ 0.8MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Bromocriptine" as an intervention, any sponsor and status, largest first.

All 47 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea46
  • drug ineffective37
  • headache35
  • vomiting33
  • dizziness31
  • pyrexia29
  • fatigue28
  • drug exposure during pregnancy25
  • neuroleptic malignant syndrome24
  • tremor22
  • somnolence20
  • diarrhoea19

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200432
200530
200634
200733
200837
200915
201019
201178
201262
201316
201416
201530
201629
201730
201823
201921
20208
202116
202222
202327
202445
202514
20268

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cycloset (Bromocriptine Mesylate)

2024 spending

$2.4M

Beneficiaries

620

2,635 claims

Per beneficiary

$3,861

$5.41 per unit

View as table
YearSpending
2020$3,948,075
2021$3,951,290
2022$3,634,070
2023$3,241,662
2024$2,394,108

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 800 on PubMed

Sponsor: Veroscience

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.